InMed Pharmaceuticals (INM) Competitors $2.31 -0.06 (-2.53%) Closing price 08/5/2025 04:00 PM EasternExtended Trading$2.44 +0.13 (+5.63%) As of 05:17 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsShort InterestTrendsBuy This Stock INM vs. RLYB, BCAB, CMMB, FNCH, PRPH, ABP, SYBX, LPCN, CASI, and BLRXShould you be buying InMed Pharmaceuticals stock or one of its competitors? The main competitors of InMed Pharmaceuticals include Rallybio (RLYB), BioAtla (BCAB), Chemomab Therapeutics (CMMB), Finch Therapeutics Group (FNCH), ProPhase Labs (PRPH), Abpro (ABP), Synlogic (SYBX), Lipocine (LPCN), CASI Pharmaceuticals (CASI), and BioLineRx (BLRX). These companies are all part of the "pharmaceutical products" industry. InMed Pharmaceuticals vs. Its Competitors Rallybio BioAtla Chemomab Therapeutics Finch Therapeutics Group ProPhase Labs Abpro Synlogic Lipocine CASI Pharmaceuticals BioLineRx Rallybio (NASDAQ:RLYB) and InMed Pharmaceuticals (NASDAQ:INM) are both small-cap medical companies, but which is the superior stock? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, valuation, risk, institutional ownership, profitability, media sentiment and dividends. Is RLYB or INM more profitable? InMed Pharmaceuticals has a net margin of -168.87% compared to Rallybio's net margin of -5,682.19%. Rallybio's return on equity of -72.31% beat InMed Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rallybio-5,682.19% -72.31% -64.78% InMed Pharmaceuticals -168.87%-107.93%-82.97% Does the media prefer RLYB or INM? In the previous week, Rallybio had 1 more articles in the media than InMed Pharmaceuticals. MarketBeat recorded 1 mentions for Rallybio and 0 mentions for InMed Pharmaceuticals. InMed Pharmaceuticals' average media sentiment score of 0.00 beat Rallybio's score of -1.00 indicating that InMed Pharmaceuticals is being referred to more favorably in the news media. Company Overall Sentiment Rallybio Negative InMed Pharmaceuticals Neutral Do analysts rate RLYB or INM? Rallybio currently has a consensus target price of $10.00, indicating a potential upside of 1,724.82%. Given Rallybio's stronger consensus rating and higher probable upside, equities analysts clearly believe Rallybio is more favorable than InMed Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rallybio 0 Sell rating(s) 4 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00InMed Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00 Which has stronger earnings & valuation, RLYB or INM? InMed Pharmaceuticals has higher revenue and earnings than Rallybio. Rallybio is trading at a lower price-to-earnings ratio than InMed Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRallybio$640K35.63-$57.78M-$1.09-0.50InMed Pharmaceuticals$4.60M1.00-$7.68M-$12.09-0.19 Do institutionals & insiders believe in RLYB or INM? 90.3% of Rallybio shares are owned by institutional investors. Comparatively, 20.1% of InMed Pharmaceuticals shares are owned by institutional investors. 8.7% of Rallybio shares are owned by insiders. Comparatively, 1.4% of InMed Pharmaceuticals shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth. Which has more volatility and risk, RLYB or INM? Rallybio has a beta of -1.12, indicating that its stock price is 212% less volatile than the S&P 500. Comparatively, InMed Pharmaceuticals has a beta of 0.29, indicating that its stock price is 71% less volatile than the S&P 500. SummaryRallybio beats InMed Pharmaceuticals on 9 of the 15 factors compared between the two stocks. Get InMed Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for INM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding INM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INM vs. The Competition Export to ExcelMetricInMed PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.75M$2.53B$5.59B$9.53BDividend YieldN/A1.77%4.71%4.14%P/E Ratio-0.199.1628.8923.88Price / Sales1.00717.24447.6498.82Price / CashN/A159.4135.6858.35Price / Book0.115.078.165.60Net Income-$7.68M$31.61M$3.25B$265.26M7 Day Performance-8.33%-0.38%1.12%-0.15%1 Month Performance-20.34%5.79%8.22%6.07%1 Year Performance-5.79%3.58%29.12%24.21% InMed Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INMInMed Pharmaceuticals0.0791 of 5 stars$2.31-2.5%N/A-13.2%$4.75M$4.60M-0.1910RLYBRallybio1.9636 of 5 stars$0.50+1.0%$10.00+1,885.3%-53.6%$20.75M$640K-0.4640Negative NewsGap UpBCABBioAtla1.8409 of 5 stars$0.35-0.2%$5.00+1,312.4%-77.4%$20.68M$11M-0.2960Upcoming EarningsCMMBChemomab Therapeutics2.1731 of 5 stars$1.09flat$8.50+679.8%-5.8%$20.55MN/A-1.4320News CoverageFNCHFinch Therapeutics GroupN/A$12.50-0.4%N/A+374.5%$20.08MN/A-1.42190PRPHProPhase Labs0.6016 of 5 stars$0.44-4.7%N/A-87.8%$19.36M$6.77M-0.35130Upcoming EarningsGap UpABPAbproN/A$0.32+1.3%$4.00+1,152.0%N/A$19.17M$180K0.0015News CoveragePositive NewsHigh Trading VolumeSYBXSynlogic1.0148 of 5 stars$1.62+1.9%N/A-11.9%$18.60M$10K-0.6580Gap DownLPCNLipocine2.6821 of 5 stars$3.33-3.2%$9.00+170.2%-38.2%$18.41M$11.20M-3.2710News CoveragePositive NewsEarnings ReportCASICASI Pharmaceuticals3.9919 of 5 stars$1.62+9.5%$4.00+146.9%-70.2%$18.20M$28.54M-0.64180News CoverageGap DownBLRXBioLineRx2.1067 of 5 stars$4.16-2.1%$26.00+525.0%-84.8%$18.12M$28.94M-0.4740 Related Companies and Tools Related Companies RLYB Alternatives BCAB Alternatives CMMB Alternatives FNCH Alternatives PRPH Alternatives ABP Alternatives SYBX Alternatives LPCN Alternatives CASI Alternatives BLRX Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:INM) was last updated on 8/6/2025 by MarketBeat.com Staff From Our PartnersINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | Sponsored[Shocking New Report] U.S. Dollar To Crash?The "Death Spiral" Threatening Your Savings But this time, it's not just Dalio ringing the alarm bells…Goldco Precious Metals | SponsoredCrypto bros: Meet your replacementLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | SponsoredGENIUS Act: Cancel Your Money?They said digital dollars were off the table. But with the GENIUS Act now federal law, private corporations—no...Priority Gold | SponsoredBanks aren’t ready for this altcoin—are you?The Secret Crypto That Billionaires Are Hoarding When these hit, the current price will look like pocket ch...Crypto 101 Media | Sponsored[Warning] Buffett Indicator hits new All-Time-HighWarren Buffett has leaned on one key indicator for decades—and it just hit an all-time high. That’s not bullis...Golden Portfolio | SponsoredThe Robotics Revolution has arrived … and one $7 stock could take off as a result.Something big is brewing in Washington. According to my research, an executive order from President Trump c...Weiss Ratings | SponsoredMarket Crash Warning: How to Protect Your Wealth Before August 12thChina tariffs hit August 12—and experts warn a market meltdown may follow. A free guide from American Alter...American Alternative | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding InMed Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share InMed Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
